ASX - By Stock
|
EMD |
Re:
Ann: Emyria receives ethics approval for EMD-RX5 Phase 3 trial
|
|
kanyekrush
|
21 |
5.1K |
3 |
18/08/22 |
18/08/22 |
ASX - By Stock
|
21
|
5.1K
|
3
|
|
ASX - By Stock
|
EMD |
Re:
Ann: EMD-RX5 demonstrates excellent safety and bioavailability
|
|
kanyekrush
|
94 |
27K |
9 |
25/05/22 |
25/05/22 |
ASX - By Stock
|
94
|
27K
|
9
|
|
ASX - By Stock
|
EMD |
Re:
Industry news
|
|
kanyekrush
|
102 |
26K |
11 |
23/05/22 |
23/05/22 |
ASX - By Stock
|
102
|
26K
|
11
|
|
ASX - By Stock
|
EMD |
Re:
Industry news
|
|
kanyekrush
|
102 |
26K |
3 |
15/02/22 |
15/02/22 |
ASX - By Stock
|
102
|
26K
|
3
|
|
ASX - By Stock
|
EMD |
Re:
Industry news
|
|
kanyekrush
|
102 |
26K |
5 |
30/01/22 |
30/01/22 |
ASX - By Stock
|
102
|
26K
|
5
|
|
ASX - By Stock
|
EMD |
Re:
Industry news
|
|
kanyekrush
|
102 |
26K |
5 |
29/01/22 |
29/01/22 |
ASX - By Stock
|
102
|
26K
|
5
|
|
ASX - By Stock
|
EMD |
Re:
Ann: Phase 1 trial commences Q1, 2022 for Emyrias ultra-pure CBD
|
|
kanyekrush
|
11 |
3.6K |
8 |
21/01/22 |
21/01/22 |
ASX - By Stock
|
11
|
3.6K
|
8
|
|
ASX - By Stock
|
EMD |
Re:
Ann: Phase 1 trial commences Q1, 2022 for Emyrias ultra-pure CBD
|
|
kanyekrush
|
11 |
3.6K |
8 |
20/01/22 |
20/01/22 |
ASX - By Stock
|
11
|
3.6K
|
8
|
|
ASX - By Stock
|
EMD |
Re:
Industry news
|
|
kanyekrush
|
102 |
26K |
9 |
07/01/22 |
07/01/22 |
ASX - By Stock
|
102
|
26K
|
9
|
|
ASX - By Stock
|
EMD |
Re:
Industry news
|
|
kanyekrush
|
102 |
26K |
9 |
23/12/21 |
23/12/21 |
ASX - By Stock
|
102
|
26K
|
9
|
|
ASX - By Stock
|
EMD |
Re:
TGA decides not to downschedule psilocybin/MDMA
|
|
kanyekrush
|
12 |
2.8K |
1 |
17/12/21 |
17/12/21 |
ASX - By Stock
|
12
|
2.8K
|
1
|
|
ASX - By Stock
|
EMD |
TGA decides not to downschedule psilocybin/MDMA
|
|
kanyekrush
|
12 |
2.8K |
4 |
15/12/21 |
15/12/21 |
ASX - By Stock
|
12
|
2.8K
|
4
|
|
ASX - By Stock
|
EMD |
Re:
EMD news articles
|
|
kanyekrush
|
129 |
30K |
0 |
09/12/21 |
09/12/21 |
ASX - By Stock
|
129
|
30K
|
0
|
|
ASX - By Stock
|
EMD |
Re:
Ann: Positive initial MDMA-analogue screening results
|
|
kanyekrush
|
7 |
2.3K |
6 |
09/12/21 |
09/12/21 |
ASX - By Stock
|
7
|
2.3K
|
6
|
|
ASX - By Stock
|
EMD |
Re:
Ann: Positive initial MDMA-analogue screening results
|
|
kanyekrush
|
7 |
2.3K |
19 |
08/12/21 |
08/12/21 |
ASX - By Stock
|
7
|
2.3K
|
19
|
|
ASX - By Stock
|
EMD |
Re:
EMD news articles
|
|
kanyekrush
|
129 |
30K |
5 |
06/12/21 |
06/12/21 |
ASX - By Stock
|
129
|
30K
|
5
|
|
ASX - By Stock
|
EMD |
Re:
EMD news articles
|
|
kanyekrush
|
129 |
30K |
14 |
06/12/21 |
06/12/21 |
ASX - By Stock
|
129
|
30K
|
14
|
|
ASX - By Stock
|
EMD |
Re:
EMD news articles
|
|
kanyekrush
|
129 |
30K |
4 |
03/12/21 |
03/12/21 |
ASX - By Stock
|
129
|
30K
|
4
|
|
ASX - By Stock
|
EMD |
Re:
Peter Thiel, Andrew Forrest and the beginning of a goobal sector boom
|
|
kanyekrush
|
90 |
23K |
6 |
25/11/21 |
25/11/21 |
ASX - By Stock
|
90
|
23K
|
6
|
|
ASX - By Stock
|
EMD |
Re:
Peter Thiel, Andrew Forrest and the beginning of a goobal sector boom
|
|
kanyekrush
|
90 |
23K |
4 |
24/11/21 |
24/11/21 |
ASX - By Stock
|
90
|
23K
|
4
|
|
ASX - By Stock
|
EMD |
Re:
Ann: Emyria receives $1,162,000 R&D Tax Incentive Refund
|
|
kanyekrush
|
8 |
1.6K |
8 |
24/11/21 |
24/11/21 |
ASX - By Stock
|
8
|
1.6K
|
8
|
|
ASX - By Stock
|
EMD |
Re:
Ann: Emyria receives $1,162,000 R&D Tax Incentive Refund
|
|
kanyekrush
|
8 |
1.6K |
11 |
24/11/21 |
24/11/21 |
ASX - By Stock
|
8
|
1.6K
|
11
|
|
ASX - By Stock
|
EMD |
Re:
Peter Thiel, Andrew Forrest and the beginning of a goobal sector boom
|
|
kanyekrush
|
90 |
23K |
5 |
23/11/21 |
23/11/21 |
ASX - By Stock
|
90
|
23K
|
5
|
|
ASX - By Stock
|
EMD |
Re:
Peter Thiel, Andrew Forrest and the beginning of a goobal sector boom
|
|
kanyekrush
|
90 |
23K |
2 |
23/11/21 |
23/11/21 |
ASX - By Stock
|
90
|
23K
|
2
|
|
ASX - By Stock
|
EMD |
Re:
Peter Thiel, Andrew Forrest and the beginning of a goobal sector boom
|
|
kanyekrush
|
90 |
23K |
2 |
23/11/21 |
23/11/21 |
ASX - By Stock
|
90
|
23K
|
2
|
|
ASX - By Stock
|
EMD |
Re:
Peter Thiel, Andrew Forrest and the beginning of a goobal sector boom
|
|
kanyekrush
|
90 |
23K |
2 |
23/11/21 |
23/11/21 |
ASX - By Stock
|
90
|
23K
|
2
|
|
ASX - By Stock
|
EMD |
Re:
Peter Thiel, Andrew Forrest and the beginning of a goobal sector boom
|
|
kanyekrush
|
90 |
23K |
8 |
22/11/21 |
22/11/21 |
ASX - By Stock
|
90
|
23K
|
8
|
|
ASX - By Stock
|
EMD |
Re:
Ann: Emyria Welcomes Tattarang as Strategic Investor
|
|
kanyekrush
|
34 |
9.0K |
6 |
22/11/21 |
22/11/21 |
ASX - By Stock
|
34
|
9.0K
|
6
|
|
ASX - By Stock
|
EMD |
Re:
EMD news articles
|
|
kanyekrush
|
129 |
30K |
4 |
17/11/21 |
17/11/21 |
ASX - By Stock
|
129
|
30K
|
4
|
|
ASX - By Stock
|
EMD |
Re:
EMD news articles
|
|
kanyekrush
|
129 |
30K |
4 |
17/11/21 |
17/11/21 |
ASX - By Stock
|
129
|
30K
|
4
|
|
ASX - By Stock
|
EMD |
Re:
EMD news articles
|
|
kanyekrush
|
129 |
30K |
2 |
17/11/21 |
17/11/21 |
ASX - By Stock
|
129
|
30K
|
2
|
|
ASX - By Stock
|
EMD |
Re:
Chart - EMD
|
|
kanyekrush
|
90 |
26K |
8 |
08/11/21 |
08/11/21 |
ASX - By Stock
|
90
|
26K
|
8
|
|
ASX - By Stock
|
EMD |
Re:
EMD news articles
|
|
kanyekrush
|
129 |
30K |
2 |
02/11/21 |
02/11/21 |
ASX - By Stock
|
129
|
30K
|
2
|
|
ASX - By Stock
|
EMD |
Re:
EMD news articles
|
|
kanyekrush
|
129 |
30K |
4 |
02/11/21 |
02/11/21 |
ASX - By Stock
|
129
|
30K
|
4
|
|
ASX - By Stock
|
EMD |
Re:
EMD news articles
|
|
kanyekrush
|
129 |
30K |
10 |
29/10/21 |
29/10/21 |
ASX - By Stock
|
129
|
30K
|
10
|
|
ASX - By Stock
|
EMD |
Re:
EMD news articles
|
|
kanyekrush
|
129 |
30K |
4 |
11/10/21 |
11/10/21 |
ASX - By Stock
|
129
|
30K
|
4
|
|
ASX - By Stock
|
EMD |
Re:
EMD news articles
|
|
kanyekrush
|
129 |
30K |
5 |
11/10/21 |
11/10/21 |
ASX - By Stock
|
129
|
30K
|
5
|
|